Literature DB >> 2321439

Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group.

U Bergholm1, H O Adami, R Bergström, M Bäckdahl, G Akerström.   

Abstract

All the 249 patients with medullary thyroid carcinoma (MTC) diagnosed during a 23-year period in Sweden were followed up completely for 4-27 years. The overall relative survival was 79.9% at 5 years after diagnosis and 68.6% at 10 years. After 5 years of follow-up, the relative survival rate was 5 percentage points higher in females than in males; 30 percentage points higher in patients aged less than 40 than in those 60-69 years at diagnosis; 24 percentage points higher in patients with familial disease detected at screening than in those with sporadic MTC; 20, 26 and 48 percentage points lower in patients with stage II, III, and IV, respectively, than in those with stage I; and almost 30 percentage points lower in the group of patients with a large tumor (greater than 3 cm) than in the group with a small one (less than 1 cm). In multivariate proportional hazards analyses of all these important determinants of outcome, the prognostic information provided by age and stage was still significant when several morphologic characteristics were taken into account (nuclear DNA content, calcitonin immunoreactivity, amyloid content, argyrophil reaction and state of the tumor capsule).

Entities:  

Mesh:

Year:  1990        PMID: 2321439

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  7 in total

1.  Prognostic factors for sporadic medullary thyroid carcinoma.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Mustafa Boyabatli
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

2.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

3.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

4.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.

Authors:  F Raue; J Kotzerke; D Reinwein; S Schröder; H D Röher; H Deckart; R Höfer; M Ritter; F Seif; H Buhr
Journal:  Clin Investig       Date:  1993-01

Review 6.  Management of lymph nodes in medullary thyroid carcinoma: A review.

Authors:  Ali Shaghaghi; Abolfazl Salari; Amirmohsen Jalaeefar; Mohammad Shirkhoda
Journal:  Ann Med Surg (Lond)       Date:  2022-09-03

7.  The relevance of somatostatin receptors in thyroid neoplasia.

Authors:  H Ahlman; L E Tisell; B Wängberg; M Fjälling; E Forssell-Aronsson; L Kölby; O Nilsson
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.